schizophrenia
Mental health · 2005–2026
26decisions
14medicines
6carried consumer input
8individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| risperidone Prevention of relapse of schizophrenia in adults following stabilisation with oral risperidone. | Mar 2026 | Recommended with restriction | no section in document |
| aripiprazole Treatment of schizophrenia in adults. The drug is also TGA-registered for maintenance treatment to prevent recurrence of manic or mixed episodes of bipolar I… | Jul 2025 | Recommended with restriction | none received |
| brexpiprazole Treatment of schizophrenia in adults. The submission requests listing of a new 0.5 mg tablet strength to facilitate dose titration in patients who require… | Jul 2025 | Recommended | 2 individuals |
| paliperidone Maintenance treatment of schizophrenia in adults. | Jul 2025 | Recommended | none received |
| risperidone Treatment of schizophrenia in adults for whom tolerability and effectiveness have been established with oral risperidone. | Mar 2024 | Recommended with restriction | none received |
| aripiprazole Maintenance treatment of schizophrenia in adults who are stabilised on aripiprazole once-monthly injection. | Dec 2024 | Recommended with restriction | 2 individuals |
| paliperidone palmitate Maintenance treatment of schizophrenia in adult patients who have been adequately treated with paliperidone palmitate 1-month or 3-month injectable product. | Mar 2022 | Recommended with restriction | 2 individuals |
| cariprazine Treatment of schizophrenia in adult patients. Proposed for acute and maintenance therapy. | Nov 2020 | Recommended with restriction | none received |
| aripiprazole Treatment of schizophrenia in adults; acute and maintenance treatment of schizophrenia and maintenance treatment to prevent recurrence of manic or mixed… | Jul 2018 | Recommended with restriction | none received |
| clozapine Schizophrenia in patients who are non-responsive to or intolerant of other neuroleptic agents (initial treatment), and continuing treatment in patients already… | Jul 2018 | Recommended with restriction | no section in document |
| quetiapine Maintenance therapy for treatment of acute mania and bipolar I disorder, and in the treatment of schizophrenia. | Jul 2018 | Recommended | no section in document |
| brexpiprazole Treatment of schizophrenia in adult patients. | Mar 2017 | Recommended with restriction | input received |
| paliperidone palmitate Treatment of patients with schizophrenia who have been adequately treated with Paliperidone one month LAI for at least four months. | Nov 2016 | Recommended with restriction | input received |
| lurasidone Treatment of schizophrenia in adults, particularly for patients not controlled satisfactorily or intolerant to other atypical antipsychotic agents, or in whom… | Mar 2015 | Recommended with restriction | none received |
| aripiprazole Maintenance treatment of schizophrenia in patients on stable doses of aripiprazole long-acting injection. | Jul 2014 | Recommended with restriction | 2 individuals |
| lurasidone hydrochloride Treatment of schizophrenia in adults. Proposed for first- and second-line treatment as an alternative to current oral atypical/second generation antipsychotics. | Mar 2014 | Not recommended | unclear |
| quetiapine A utilisation review of antipsychotics, specifically examining the use of quetiapine 25mg formulation. The PBAC review found inappropriate use of quetiapine… | Aug 2013 | Recommended with restriction | no section in document |
| asenapine treatment of schizophrenia in adults | Jul 2011 | Recommended with restriction | unclear |
| sertindole treatment of schizophrenia in people who have had prior treatment with at least one other antipsychotic | Mar 2011 | Not recommended | unclear |
| paliperidone palmitate treatment of schizophrenia | Nov 2010 | Recommended | unclear |
| olanzapine pamoate monohydrate treatment of schizophrenia in adult patients who can be stabilised with oral olanzapine | Jul 2009 | Recommended with restriction | no section in document |
| paliperidone schizophrenia, including acute treatment and recurrence prevention | Nov 2007 | Recommended | no section in document |
| paliperidone Treatment of schizophrenia, including acute treatment and recurrence prevention. | Nov 2007 | Recommended with restriction | no section in document |
| ziprasidone hydrochloride treatment of schizophrenia | Nov 2006 | Recommended with restriction | no section in document |
| ziprasidone hydrochloride Treatment of schizophrenia. | Nov 2006 | Recommended with restriction | no section in document |
| risperidone Treatment of schizophrenia in patients whose illness requires supervision and treatment at hospital outpatient clinics or affiliated mental health centres. | Jul 2005 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 16 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.